Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease
BackgroundInflammatory bowel disease (IBD) is a chronic relapsing-remitting disease. An adverse immune reaction toward the intestinal microbiota is involved in the pathophysiology and microbial perturbations are associated with IBD in general and with flares specifically. Although medical drugs are...
Main Authors: | Heike E. F. Becker, Karlijn Demers, Luc J. J. Derijks, Daisy M. A. E. Jonkers, John Penders |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1107976/full |
Similar Items
-
Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease
by: Matthijs Bekkers, et al.
Published: (2021-10-01) -
Homeostasis and Dysbiosis of the Intestinal Microbiota: Comparing Hallmarks of a Healthy State with Changes in Inflammatory Bowel Disease
by: Jasminka Talapko, et al.
Published: (2022-12-01) -
The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
by: Floris Imhann, et al.
Published: (2019-01-01) -
INFLAMMATORY BOWEL DISEASE
by: I Gusti Ayu Mahaprani Danastri, et al.
Published: (2013-02-01) -
Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases
by: Hala Elzayat, et al.
Published: (2023-07-01)